Using PET-CT in the restaging of primitive mediastinal B-cell lymphoma (PMBCL) after chemotherapy: which criteria should we use?
Francesca Giunta, G Bisi, Michele Balma, Michela Zotta, Annalisa Chiappella(Palmetto Hematology Oncology), Umberto Ricardi(University of Turin), Andrea Riccardo Filippi(University of Turin), Massimo Menga, Marco Ladetto(University of Turin), M. Bellò, Roberto Passera(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Umberto Vitolo(Candiolo Cancer Institute)
PubMed
June 1, 2015
Cited by 3
Related Papers
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
|The Lancet Oncology|2020|1.1k
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2015|920
Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2017|736
Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document
|Radiotherapy and Oncology|2020|646